20,573 Shares in Immunovant, Inc. (NASDAQ:IMVT) Purchased by F M Investments LLC

F M Investments LLC bought a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 20,573 shares of the company’s stock, valued at approximately $510,000.

Several other large investors have also recently bought and sold shares of IMVT. KBC Group NV boosted its holdings in shares of Immunovant by 60.1% in the fourth quarter. KBC Group NV now owns 3,099 shares of the company’s stock valued at $77,000 after acquiring an additional 1,163 shares in the last quarter. Rhumbline Advisers boosted its stake in Immunovant by 1.5% during the 4th quarter. Rhumbline Advisers now owns 80,932 shares of the company’s stock valued at $2,005,000 after purchasing an additional 1,188 shares in the last quarter. Swiss National Bank boosted its stake in Immunovant by 1.2% during the 4th quarter. Swiss National Bank now owns 100,800 shares of the company’s stock valued at $2,497,000 after purchasing an additional 1,200 shares in the last quarter. Tyro Capital Management LLC increased its position in shares of Immunovant by 0.6% during the 3rd quarter. Tyro Capital Management LLC now owns 252,149 shares of the company’s stock valued at $7,189,000 after purchasing an additional 1,529 shares during the period. Finally, Sei Investments Co. raised its stake in shares of Immunovant by 4.0% in the 4th quarter. Sei Investments Co. now owns 40,456 shares of the company’s stock worth $1,002,000 after buying an additional 1,541 shares in the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

Wall Street Analysts Forecast Growth

IMVT has been the topic of a number of research analyst reports. Wells Fargo & Company lowered their target price on Immunovant from $47.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Wolfe Research cut shares of Immunovant from an “outperform” rating to a “peer perform” rating in a research note on Friday, January 3rd. Bank of America dropped their target price on shares of Immunovant from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Immunovant in a report on Thursday, March 20th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $41.00.

Immunovant Trading Down 0.7 %

Shares of IMVT stock opened at $14.68 on Friday. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of -5.60 and a beta of 0.81. Immunovant, Inc. has a 1-year low of $12.72 and a 1-year high of $34.47. The stock’s fifty day simple moving average is $18.57 and its 200-day simple moving average is $24.06.

Immunovant (NASDAQ:IMVT) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.08). On average, sell-side analysts predict that Immunovant, Inc. will post -2.69 EPS for the current year.

Insider Buying and Selling

In other Immunovant news, insider William L. Macias sold 2,383 shares of Immunovant stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $23.83, for a total transaction of $56,786.89. Following the completion of the sale, the insider now owns 359,408 shares of the company’s stock, valued at $8,564,692.64. This trade represents a 0.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. The trade was a 21.11 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 54,394 shares of company stock worth $956,666. 5.90% of the stock is owned by company insiders.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.